The RAPS learning platform provider will be upgrading its security posture. This will take the system off-line from 20 July through the end of the day 23 July. This will affect any Online Course, eBook, and Virtual Program Attendance. Thank you for your patience.
Case Study: A Novel Investment Partnering Solution for Sharing Development Risk
Posted 01 December 2008 | By
On 24 July 2008, on its earnings call, Eli Lilly and Company announced its intention to partner with TPG-Axon and NovaQuest for the development of Lilly's two lead molecules for the treatment of Alzheimer's disease.1 One molecule is a gamma-secretase small
molecule and the other is an antibody targeted against A-beta. Both molecules are designed to modify the progression of mild to moderate Alzheimer's disease.